# Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

> **NCT03141073** · PHASE3 · COMPLETED · sponsor: **Hua Medicine Limited** · enrollment: 767 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** HMS5552
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03141073
- **Lead sponsor:** Hua Medicine Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-15
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 767 (ACTUAL)
- **Last updated:** 2021-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03141073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03141073, "Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03141073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*